Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 26, Issue 5, pp. 1054-1064
PubMed
Published By
Print ISSN
Online ISSN
History
- Received May 24, 2019
- Revision received September 21, 2019
- Accepted November 7, 2019
- Published first November 15, 2019.
Article Versions
- Previous version (November 15, 2019 - 06:47).
- Previous version (January 9, 2020 - 07:22).
- You are viewing the most recent version of this article.
Copyright & Usage
©2019 American Association for Cancer Research.
Author Information
- Paige M. Glumac1,
- Joseph P. Gallant1,
- Mariya Shapovalova1,
- Yingming Li2,3,
- Paari Murugan3,
- Shilpa Gupta4,
- Ilsa M. Coleman5,
- Peter S. Nelson5,
- Scott M. Dehm2,3, and
- Aaron M. LeBeau1,2,*
- 1Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota.
- 2Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
- 3Departments of Laboratory Medicine and Pathology and Urology, University of Minnesota Medical School, Minneapolis, Minnesota.
- 4Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.
- 5Fred Hutchinson Cancer Research Center, Seattle, Washington.
- ↵*Corresponding Author:
Aaron M. LeBeau, University of Minnesota, 312 Church St. SE, Minneapolis, MN 55455-0217. Phone: 612-301-7231; Fax: 612-625-8408; E-mail: alebeau{at}umn.edu
March 2020
Volume 26, Issue 5
Volume 26, Issue 5
Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer
Jump to section
Advertisement